Navigation Links
Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings
Date:4/5/2011

PARSIPPANY, N.J., April 5, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading integrated global pharmaceutical company, announced today that the Company intends to release its first quarter 2011 financial results on Wednesday, April 27, 2011 prior to the open of the U.S. financial markets.  The Company will also host a conference call and webcast at 8:30 a.m. Eastern Time on April 27, 2011 to discuss its financial results and provide an update on the Company's outlook for 2011.  The dial-in number to access the call is US/Canada (877) 251-7980, International (706) 643-1573.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Time on May 11, 2011.  The replay may be accessed by dialing (800) 642-1687 and entering pass code 56748589.  From international locations, the replay may be accessed by dialing (706) 645-9291 and entering the same pass code.  To access the webcast, go to Watson's Investor Relations Web site at http://ir.watson.com.  A replay of the webcast will also be available.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press releases and other company information, visit the Watson Web site at http://www.watson.com

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:
Investors:
Patty Eisenhaur
Watson Pharmaceuticals, Inc.
(973) 355-8141

Media:
Charlie Mayr
Watson Pharmaceuticals, Inc.
(973) 355-8483


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... to their offering. ... The ablation device global market is expected to grow at ... Ablation is the minimally invasive therapeutic tissue excision procedure ... tissue removal, to the removal of abnormally conducting cardiac tissue in ...
(Date:3/29/2017)... , March 29, 2017   Dynatronics Corporation ... the appointment of Cynthia L. McHenry ... be responsible for leading Dynatronics manufacturing, distribution, and ... report to Dynatronics, CEO Kelvyn H. Cullimore, ... an extensive search process conducted by the company ...
(Date:3/29/2017)... , March 29, 2017 FinancialBuzz.com News Commentary  ... Data published in a research ... market will reach a value of USD 55.8 billion by 2025. The ... the United States and a more open approach towards cannabis ... , Florida , North Dakota , ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 29, 2017 , ... AngioGenesis Labs sold 300 bottles of ... Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results while doing a ... over the counter heart healthy drink, can reduce Arterial Plaque, Lower Blood Pressure, ...
(Date:3/29/2017)... ... ... Dr. Angela Cotey, a noted general dentist in Mt. Horeb, is now ... without a referral. Dr. Cotey knows that interceptive orthodontics in Mt. Horeb, ... receive early treatment, they may achieve straight teeth with less treatment in their teenage ...
(Date:3/29/2017)... Baltimore, MD (PRWEB) , ... March 29, 2017 , ... ... Maryland, is proud to announce the finalization of the company’s executive management team with ... team and leading operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the ... Taffet Moelis, W’81, have made a $10 million gift to establish the Ken ... will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic ...
Breaking Medicine News(10 mins):